| Chronic Obstructive Airway Disease
Nucala vs Ohtuvayre
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Nucala vs Ohtuvayre with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOhtuvayre has a higher rate of injection site reactions vs Nucala based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ohtuvayre but not Nucala, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nucala
Ohtuvayre
At A Glance
SC injection
Every 4 weeks
IL-5 antagonist
Oral inhalation
Twice daily
PDE3/PDE4 inhibitor
Indications
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Chronic Obstructive Airway Disease
- Eosinophilic granulomatosis with polyangiitis
- Hypereosinophilic syndrome
- Chronic Obstructive Airway Disease
Dosing
Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.
Asthma (6-11 years) 40 mg SC once every 4 weeks.
Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.
Chronic Obstructive Airway Disease 3 mg (one unit-dose ampule) twice daily, once in the morning and once in the evening, via oral inhalation using a standard jet nebulizer with a mouthpiece.
Contraindications
- History of hypersensitivity to mepolizumab or excipients in the formulation
- Hypersensitivity to ensifentrine or any component of this product
Adverse Reactions
Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema
Serious herpes zoster
Postmarketing hypersensitivity reactions including anaphylaxis
Most common (>=1%) Back pain, hypertension, urinary tract infection, diarrhea
Serious Paradoxical bronchospasm, psychiatric events including suicidality
Pharmacology
Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.
Ensifentrine is a dual inhibitor of PDE3 and PDE4 enzymes; inhibition results in accumulation of intracellular cAMP and/or cGMP, producing downstream bronchodilatory and anti-inflammatory signaling effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nucala
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
Ohtuvayre
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Nucala
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Ohtuvayre
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Nucala
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ohtuvayre
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NucalaView full Nucala profile
OhtuvayreView full Ohtuvayre profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.